Corporate Market Snapshot: Tianyu Bio- (603717.SS)
During the 24‑hour period concluding at 03:07 AM Central Europe on Friday, 23 October 2026, Tianyu Bio- (603717.SS) closed on a flat day, with no change in price from the previous close. At the moment of writing, one share of Tianyu Bio- is available for approximately CNY 5.46 on the most frequently used exchanges.
Trading Volume and Capitalisation
- Total Shares Outstanding: 291.1 million
- Market Capitalisation: CNY 1.6 billion
- Volume Traded in the Last 24 Hours: CNY 35.3 million
- Percentage Change Since Last Month‑End: –5.72 %
The stock’s average price over the last 200 trading days, a common technical indicator, sits at CNY 6.17. Over the past 52 weeks, Tianyu Bio- reached a peak of CNY 10.24 on 14 November 2025 and has dipped to a low of CNY 4.74 on 21 July 2026.
Comparative Performance in the Sector
The surrounding peer group has shown similar price stability during the same timeframe:
| Stock | Ticker | 24‑Hour Change | Current Price | Market Capitalisation | P/E Ratio |
|---|---|---|---|---|---|
| Guotong | 002205.SZ | Flat 0 % | CNY 10.24 | CNY 1.9 bn | — |
| Harbin Air Conditioning | 600202.SS | Flat 0 % | CNY 6.13 | CNY 1.9 bn | — |
| Beijing Yupont Electric Power | 688597.SS | Flat 0 % | CNY 5.93 | CNY 1.9 bn | 375.18 |
| Jiangsu Maysta Chemical | 603041.SS | Flat 0 % | CNY 10.45 | CNY 2 bn | 31.8 |
| Lzzj | 002535.SZ | Flat 0 % | CNY 2.75 | CNY 2 bn | — |
Narrative Context
The absence of price movement for Tianyu Bio- and its peers indicates a period of market consolidation. Investors appear to be waiting for fresh catalysts—whether from earnings releases, regulatory updates, or macroeconomic data—before committing to a directional stance. The modest decline of nearly six percent from the end of the previous month suggests that the market may be positioning for a potential rebound, contingent on forthcoming developments within the biotechnology sector.
In the broader landscape, the fact that Tianyu Bio- trades at a price per share roughly half its 52‑week low underlines the significant upside potential that could attract speculative interest if the company delivers on its product pipeline or secures strategic partnerships. Conversely, the high price‑to‑earnings ratios observed in the sector, particularly for Beijing Yupont Electric Power, point to a valuation premium that could temper enthusiasm among value‑oriented investors.
This report synthesises publicly available trading data to provide a clear, formal overview of Tianyu Bio- and its contemporaries within the Chinese equity market.
